đź’¨ Abstract

On May 7, 2025, EyePoint Pharmaceuticals (EYPT) announced a net loss of $45.2 million (65 cents per share) for Q1, meeting analyst expectations. Despite the loss, the company's revenue of $24.5 million exceeded forecasts, with analysts predicting only $5.5 million. This information was automatically generated based on data from Zacks Investment Research.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖

Powered by MessengerX.io